Dr Johnson Jianzhong Liu

Research Interests:

The broad interest of the lab is concerning cancer pharmacology, experimental therapeutics, targeted cancer therapy, pharmacokinetics, drug transport, chemotherapy-induced neuropathy and cancer risk-related genetic polymorphisms. In particular, we have been involving in the preclinical development of anticancer agents, including small molecules targeting Wnt signalling, copper chelators, platinum/gold/silver-based complexes, vascular-disrupting flavonoids and mulberry fruit extracts using a variety of in vitro and in vivo approaches. We are among the first to identify the links of copper transporters and organic cation transporters with chemotherapy-induced neurotoxicity, and lung cancer risk related genetic polymorphisms in Chinese Han population. We have current research projects for PhD, Masters, Honours and ILP students on the topics of targeting Wnt signalling and drug transporters in cancer therapy.

Membership:

• Australasian Society of Clinical & Experimental Pharmacologists & Toxicologists
• Australasian Clinical Trials Alliance
• American Association for Cancer Research